[1]李生娇,吕春堂,郭伟,等.125I标记的血管内皮生长因子受体3多抗在大鼠体内的分布研究[J].国际放射医学核医学杂志,2007,31(2):65-67.
　LI Sheng-jiao,LU Chun-tang,GUO Wei,et al.Study on 125I-vascular endothelial growth factor receptor-3 polyclonal antibody biod-istribution in rat[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(2):65-67.
点击复制

125I标记的血管内皮生长因子受体3多抗在大鼠体内的分布研究(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
31
期数:
2007年第2期
页码:
65-67
栏目:
实验核医学
出版日期:
1900-01-01

文章信息/Info

Title:
Study on 125I-vascular endothelial growth factor receptor-3 polyclonal antibody biod-istribution in rat
作者:
李生娇1;  吕春堂2;  郭伟1;  韩玲3;  谢卫红1;  任国欣1
1. 200011 上海, 上海交通大学医学院附属第九人民医院口腔医学院口腔颌面外科上海市口腔医学研究所;
2. 200433 上海, 第二军医大学附属长海医院口腔科;
3. 200433 上海, 第二军医大学海医系放射医学教研室
Author(s):
LI Sheng-jiao1;  LU Chun-tang2;  GUO Wei1;  HAN Ling3;  XIE Wei-hong1;  REN guo-xin1
1. Department of Oral and Maxillofacial Surgery, School of Stomatology, Ninth People’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Research Institute of Stomatology, Shanghai 200011, China;
2. Department of Stomatology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China;
3. Department of Radiation Medicine, Faculty of Naval Medicine, Second Military Medical University, Shanghai 200433, China
关键词:
碘放射性同位素; 血管内皮生长因子受体3; 前哨淋巴结; 大鼠
Keywords:
Iodine radioisotopes; Vascular endothelial growth factor receptor-3; Sentinal lymph node; Rat
分类号:
R817.1
摘要:
目的 研究血管内皮生长因子受体3多抗(Flt4 PcAb)在大鼠体内的分布,为进一步应用Flt4 PcAb进行前哨淋巴结(SLN)的特异性定位奠定基础。方法 应用氯胺T法对Flt4 PcAb行125I标记;将125I-Flt4 PcAb经大鼠足背皮下注射后不同时间分批处死大鼠,取血液、腋窝淋巴结及主要脏器测量其放射性计数,经衰变校正后计算每克组织的百分注射剂量率(%ID/g),观察标记物的生物学分布。结果 125I-Flt4 PcAb的标记率达46.5%,放射性比活度为1.72×1012Bq/g,放射性化学纯度达96.7%;大鼠体内分布实验显示:125I-Flt4 PcAb主要分布于腋窝淋巴结及血液中,其余脏器较低;注射后16h内腋窝淋巴结与血液单位质量的放射性比值均大于2.5。结论 ①应用氯胺T法可以成功标记Flt4 PcAb;②皮下注射后Flt4 PcAb的体内分布表现为淋巴结浓集;③本实验为进一步应用Flt4 PcAb进行SLN的特异性定位奠定了基础。
Abstract:
Objective To study the biodistribution of 125I-Flt4 PcAb in rat and to establish the foundation of sentinel lymph node (SLN) exceptional orientation. Methods Flt4 PcAb was labeled with 125I via chloramine T method. 125I-Flt4 PcAb was subcutaneous injected in dorsum of foot in rats. The rats were killed at different stages after injection and the popliteal lymph nodes and major organs were taken out, then the radioactivity count of those organs and lymph nodes were measured. Results The labeling efficiency was 46.5%. The specific activity and the radiochemical purity of 125I-Flt4 PcAb were 1.72×1012Bq/g and 96.7% respectively. It showed higher distribution in popliteal lymph nodes and blood than the other organs. The radioactivity ratio of popliteal lymph node to blood was more than 2.5 in 16 hours after injection. Conclusions:(1)It was successful to label Flt4 PcAb with 125I via chloramine T method.(2)Flt4 PcAb would concentrate in lymph node after subcutaneous injection. (3)This study provided experimental basis for SLN exceptional orientation with Flt4 PcAb.

参考文献/References:

1 李生娇,吕春堂,周中华,等.125I标记抗Flt4多抗的制备及对淋巴结定位的动物实验.口腔颌面外科杂志,2004,14(1):24-26.
2 Jussia L, Vahola R, Partanen TA, et al. Lymphatic endothelium and kaposi’s sarcoma spindle ceils detected by antibodies against the vascular endothelial growth factor receptor-3. Cancer Res,1998, 58(8):1599-1604.
3 周申.核医学.第四版,北京:人民卫生出版社,1996.26.
4 Ballou B, Beiland J, Levine G, et al. Tumor localization using F(ab) 2 from a monoclonal IgM antibody:Pharmacokinetics. J Nucl Med, 1985, 26(3):283-292.
5 Werner JA, Dunne AA, Ranmaswamy A, et al. The sentinel node concept in head and neck squamous cell carcinoma cell carcinoma critical analysis in 100 patients. Laryngorhinootologie, 2002, 81(1):31-39.
6 Zhu H, Jain RK, Baxter LT.Tumor pretargeting for radioimmunodetection and radioimmunotherapy. J Nucl Med, 1998, 39(1):65-76.

相似文献/References:

[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
　Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]邓艳,张伟.125I-碘酞酸盐临床应用进展[J].国际放射医学核医学杂志,2016,40(3):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
　Deng Yan,Zhang Wei.125I-iothalamate clinical applications[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
[3]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
　Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[4]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
　yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[5]刘娇,程兵,常伟,等.非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J].国际放射医学核医学杂志,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
　Liu Jiao,Cheng Bing,Chang Wei,et al.Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
[6]徐蓉生,梅艳,赵力威,等.B超引导下术中125I粒子植入治疗晚期胰腺癌的疗效评价[J].国际放射医学核医学杂志,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
　Xu Rongsheng,Mei Yan,Zhao Liwei,et al.Evaluation of 125I particle implantation in the treatment of patients with advanced pancreatic neoplasms using B ultrasound-guided surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
[7]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
　Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[8]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
　Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[9]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
　Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
[10]胡小春,蒋宁一,李敬彦,等.硒对经131I治疗Graves病患者血清甲状腺过氧化物酶抗体水平的影响[J].国际放射医学核医学杂志,2015,39(2):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
　Hu Xiaochun,Jiang Ningyi,Li Jingyan,et al.Effect of additional selenium on the levels of serum thyroid peroxidase antibody in patients with Graves disease treated with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]

备注/Memo

备注/Memo:
收稿日期:2006-06-30。
基金项目:上海市重点学科(优势学科)建设项目资助(Y0203)
通讯作者:郭伟(E-mail:guoweicn@yahoo.com)
更新日期/Last Update: 1900-01-01